VIVOPOWER’S TEMBO SECURES FULL ON ROAD HOMOLOGATION FOR ITS TEMBO TUSKER 100% ELECTRIC VEHICLES IN US$10 bn AUSTRALASIAN PICK UP TRUCK MARKET
18 nov. 2024 07h50 HE
|
VivoPower International PLC
Tembo Tusker is only the 2nd full electric utility vehicle pick up truck to receive full on road homologation VTA regulatory approval in Australia Tuskers can now be driven on road and off road in...
Travere Therapeutics Reports First Quarter 2024 Financial Results
06 mai 2024 16h01 HE
|
Travere Therapeutics, Inc.
FDA grants Priority Review for sNDA to convert FILSPARI® (sparsentan) from accelerated approval to full approval for the treatment of IgAN in the U.S.; PDUFA target action date of September 5, 2024 ...
Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis
14 mars 2024 16h15 HE
|
Madrigal Pharmaceuticals, Inc.
Rezdiffra becomes the first and only medication approved by the FDA for the treatment of NASH (also known as “MASH”)Accelerated approval was based on Phase 3 data demonstrating that Rezdiffra improved...
EzFill Receives Approval from Three Miami Condo Associations to Offer Fueling to Residents of 600+ Units.
29 févr. 2024 12h00 HE
|
EzFill Holdings Inc.
Will Be Resident’s Exclusive Mobile Fueling Provider MIAMI, FL, Feb. 29, 2024 (GLOBE NEWSWIRE) -- EzFill Holdings, Inc. (“EzFill” or the “Company”) (NASDAQ: EZFL), a pioneer and emerging leader in...
Orphalan announces China NMPA’s approval of its trientine tetrahydrochloride product for the treatment of Wilson disease
18 janv. 2024 03h00 HE
|
Orphalan
Orphalan announces China NMPA’s approval of its trientine tetrahydrochloride product for the treatment of Wilson disease Paris, France 18 January, 2024 - Orphalan SA (“Orphalan” or “the Company”),...
Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE®
02 nov. 2023 10h37 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Tiziana Life Sciences Announces Allowance By FDA For At-Home Dosing Of Intranasal Foralumab For Multiple Sclerosis Treatment
18 oct. 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
Patients In the Intermediate Size Patient Population Expanded Access (EA) Program Will Receive Intranasal Foralumab As Part of the At-Home Dosing InitiativeGreater Than 1 year Safety Exposure to...
GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IBRX
27 juil. 2023 11h33 HE
|
The Rosen Law Firm PA
NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between May 23, 2022 and...
Pfizer’s Litfulo Poised to Follow Similar Trajectory as Eli Lilly/Incyte’s Olumiant for the Treatment of Severe Alopecia Areata
11 juil. 2023 09h58 HE
|
Spherix Global Insights
Exton, Pennsylvania, July 11, 2023 (GLOBE NEWSWIRE) -- In June 2022, Eli Lilly and Incyte’s Olumiant became the first and only approved advanced systemic treatment for adults with severe alopecia...
Arch Biopartners Receives Permission From U.S. FDA to Proceed With Phase II Acute Kidney Injury Trial
27 juin 2023 07h15 HE
|
Arch Biopartners
Approval from FDA to initiate Phase II trial with LSALT peptide to target cardiac surgery-associated acute kidney injury (CS-AKI)LSALT peptide targets dipeptidase-1 (DPEP-1), an enzyme known to...